I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Discussion is good but we can only discuss what we know or what info JB has given us. Speculation beyond that is unproductive. As far as competition, if you believe the hard numbers JB has given to us then we have the edge in several areas:
1) Cheaper to build - Important cost factor in profitability and expandability.
2) More Automated - Less labor costs and more efficient.
3) Better output fuel quality - also selectable and self-powered.
4) Higher volume processor - efficient
5) Smaller footprint - can I say efficient again?
6) The only publicly traded company - Try to invest in the others - this is OUR opportunity.
7) The only franchise model - fast market entry with lower cash drain.
I do wish some of the longs here would try to act like they own and represent a NASDAQ company in their responses. This is not a "game" or a "game over" stock. Forget everything you learned about momo penny stocks rise above the taunts from those who do not believe JB's statements.
Great post - I agree with you. Thanks
Acro, Inc. Receives Purchase Order for ACRO-ETK5 Plus Explosives Detection Kit From Government Agency
Date : 05/03/2010 @ 9:03AM
Source : MarketWire
Stock : Acro, Inc. (ACRI)
Quote : 0.064 0.004 (6.67%) @ 8:40AM
Acro, Inc. Receives Purchase Order for ACRO-ETK5 Plus Explosives Detection Kit From Government Agency
CAESAREA, ISRAEL -- (Marketwire)
05/03/10
Acro, Inc. (OTCBB: ACRI), a leading manufacturer of explosive detection solutions for the homeland security market and related sectors, today announced a new purchase order for its popular ACRO-ETK5 Plus explosives detection kit from an international government agency. The purchase order will be shipped in two weeks, and will be used in the field to detect a wide range of materials used in explosives.
"This product has been successfully used by Israeli Port Authorities and security forces of other countries around the world," said Gadi Aner, President and Chief Executive Officer of Acro, Inc. "This newest purchase order demonstrates our ability to successfully grow our base of customers and increase market adoption for our products."
The ETK5 Plus enables simple, rapid and reliable detection of persons engaged in preparing, handling or carrying explosive charges and allows for fast screening of suspects in the field. The kit aids in detection through exposure and proof of contact contamination of various surfaces by explosives.
About Acro:
Acro, Inc. develops explosives detection technologies and manufactures relevant products. In addition to the explosives detectors that are currently marketed by Acro, the company continues to develop proprietary technologies for the HLS market. Acro's Advisory Board includes Nobel Prize laureate Prof. K. Barry Sharpless and Prof. Richard A. Lerner, President and CEO of The Scripps Research Institute, one of the most influential scientific institutes worldwide. For more information about Acro, visit www.AcroSec.com.
Forward-Looking Statement
This press release
contains forward-looking statements concerning our marketing and operations plans. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. All forward-looking statements in this press release are made based on management's current expectations and estimates, which involve risks, uncertainties and other factors that could cause results to differ materially from those expressed in forward-looking statements. These statements involve a number of risks and uncertainties including, but not limited to, risks related to the evolving homeland security market, general economic conditions and other risk factors
. Acro does not undertake any obligation to update forward-looking statements made herein.
For more information please contact
Acro, Inc.
info@AcroSec.com
Many of the answers to your questions have been answered on JohnB facebook page. You are free to join all you need to do is provide a real name.
Remains in stealth mode. Will take news or good financial reports to get it going again IMHO.
Not much of a dip from the 52 week high. Looking really strong.
Nice chart - thanks
Would it be easier just to take a screen shot of the program you use by bring the window to the front (active) then use the "Alt"+"Prt Scr" keys, then paste it and crop it in a paint program?
I appreciate your conservatism and your posts so please keep up the good work.
That video is very well done. Hyundai (HHI) has the deep pockets and RZ has the technology. CEO and several top staff of a 20 billion dollar company travel all the way from Korea to Utah to meet with RZ (that alone says a lot to me). Making the right connections is everything for a small company with a global vision. I think we have a winner just have to wait for the market to figure it out.
Well the PR is also on their website and is dated today. Minor error either way but I agree it need to be corrected.
It is in the "About Mesoblast" section of today's news...
Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology.
Not trying to be picky but Mesoblast owns 38.4% of Angioblast;) I don't post/trade enough to pay for ihub but you could PM me your email if you want to. Thanks.
MESOBLAST COMPLETES ENROLMENT FOR FIRST SPINAL FUSION TRIAL
Well funded for product commercialisation
Melbourne, Australia; 30 April 2010: Australia’s regenerative medicine company, Mesoblast
Limited (ASX:MSB; ADR:MBLTY),today announced it had cash reserves of $12.6 million for the
reporting period ended 31 March 2010. The results are in line with expectations and reflect prudent cash management and tight control of resources.
During the current quarter, Mesoblast and its United States-based associate company, Angioblast
Systems, have continued to make strong progress in their respective clinical programs for spinal
fusion, heart failure, and bone marrow transplantation.
Mesoblast’s first trial evaluating its proprietary allogeneic, or “off-the-shelf”, stem cells for posterolateral lumbar spinal fusion, at New York’s Hospital for Special Surgery, has now completed enrolment, and has been fully reviewed by the Data Safety and Monitoring Board. This trial compared the safety and efficacy of Mesoblast’s NeoFuse™ allogeneic stem cell product on one side with the standard-of-care, autograft bone, on the other side in the same patient.
The results showed that implantation of the cells was safe and was associated with earlier
generation of new bone formation and fusion which was robust, as determined by CT scan. Patients continue to be followed and to date no cell-related adverse events have occurred. At 6 months of follow-up, 3/5 sites (60%) that received the lowest dose tested of NeoFuse™ demonstrated fusion, as determined by bone bridging between two vertebrae whereas only 1/7 sites (14%) which received autograft demonstrated fusion.
These initial results are very encouraging, and support prior preclinical data which have shown that Mesoblast’s allogeneic cells generate faster fusion in the lumbar and cervical spine than the
autograft standard-of-care.
Mesoblast’s current Phase 2 trial for minimally-invasive posterior lumbar interbody fusion is fully funded and continues to recruit rapidly. The results from this second trial will form the basis for pivotal trial design in support of Mesoblast’s activities to commercialise a lumbar spinal fusion product.
About Mesoblast
Mesoblast Limited (ASX:MSB;ADR:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and
technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology.
Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the
rapid and successful completion of clinical milestones. www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
+ See chapter 19 for defined terms.
24/10/2005 Appendix 4C Page 1
Rule 4.7B
Appendix 4C
Quarterly report
for entities admitted
on the basis of commitments
Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.
Name of entity
Mesoblast Limited
ABN Quarter ended (“current quarter”)
68 109 431 870 31 March 2010
Consolidated statement of cash flows
Cash flows related to operating activities
Current quarter
$A’000
Year to date
(9
months)
$A’000
1.1 Receipts from customers:
• Government commercial ready grant
3
3
1.2 Payments for:
(a) staff costs
(b) advertising and market
(c) research and development
(d) leased assets
(e) other working capital
(242)
-
(refer 1.7 below)
-
(669)
(555)
-
(refer 1.7 below)
-
(1,674)
1.3 Dividends received
1.4 Interest and other items of a similar nature
received
158 457
1.5 Interest and other costs of finance paid
1.6 Income taxes paid
1.7 Other :
? commercialisation costs
(includes R&D and support costs)
(1,480)
(4,428)
Net operating cash flows (2,230) (6,197) Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
+ See chapter 19 for defined terms.
Appendix 4C Page 2 24/10/2005
Current quarter
$A’000
Year to date
(9
months)
$A’000
1.8 Net operating cash flows (carried forward) (2,230) (6,197)
Cash flows related to investing activities
1.9 Payment for acquisition of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
(0)
(58)
(18)
(0)
(240)
(69)
1.10 Proceeds from disposal of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
1.11 Loans to other entities (10) (12)
1.12 Loans repaid by other entities
1.13 Other (provide details if material)
Net investing cash flows
(86)
(321)
1.14 Total operating and investing cash flows (2,316) (6,518)
Cash flows related to financing activities
1.15 Proceeds from issues of shares, options, etc. 288 2,614
1.16 Proceeds from sale of forfeited shares
1.17 Proceeds from borrowings
1.18 Repayment of borrowings
1.19 Dividends paid
1.20 Other (provide details if material)
Net financing cash flows
288 2,614
Net increase (decrease) in cash held
(2,028) (3,904)
1.21 Cash at beginning of quarter/year to date 14,653 16,526
1.22 Exchange rate adjustments to item 1.21 (20) (17)
1.23 Cash at end of quarter 12,605 12,605 Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
+ See chapter 19 for defined terms.
24/10/2005 Appendix 4C Page 3
Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related
entities
Current quarter
$A'000
1.24
Aggregate amount of payments to the parties included in item 1.2
(141)
1.25
Aggregate amount of loans to the parties included in item 1.11
(10)
1.26
Explanation necessary for an understanding of the transactions
Ref 1.24 = Payments made to directors are as follows:
$A’000
Brian Jamieson = 30
Donal O’Dwyer = 15
Byron McAllister = 15
Michael Spooner = 15
Silviu Itescu = 66
Total = 141
Ref 1.25: Repayment of inter-entity loan to Angioblast Systems Inc (investment).
Non-cash financing and investing activities
2.1 Details of financing and investing transactions which have had a material effect on
consolidated assets and liabilities but did not involve cash flows
N/A
2.2 Details of outlays made by other entities to establish or increase their share in businesses in
which the reporting entity has an interest
N/A
Financing facilities available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
Amount available
$A’000
Amount used
$A’000
3.1 Loan facilities
- -
3.2 Credit standby arrangements
- - Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
+ See chapter 19 for defined terms.
Appendix 4C Page 4 24/10/2005
Reconciliation of cash
Reconciliation of cash at the end of the quarter (as
shown in the consolidated statement of cash flows)
to the related items in the accounts is as follows.
Current quarter
$A’000
Previous quarter
$A’000
4.1 Cash on hand and at bank 79 216
4.2 Deposits at call 1,212 646
4.3 Bank overdraft - -
4.4 Other (term deposits < 1 year maturity) 11,314 13,791
Total: cash at end of quarter (item 1.23) 12,605 14,653
Acquisitions and disposals of business entities – N/A
Acquisitions
(Item 1.9(a))
Disposals
(Item 1.10(a))
5.1 Name of entity
5.2 Place of
incorporation or
registration
5.3 Consideration for
acquisition or
disposal
5.4 Total net assets
5.5 Nature of business
Compliance statement
1 This statement has been prepared under accounting policies which comply with
accounting standards as defined in the Corporations Act (except to the extent that
information is not required because of note 2) or other standards acceptable to ASX.
2 This statement gives a true and fair view of the matters disclosed.
Sign here: ............................................................ Date: .....30 April 2010..............
(Company Secretary)
Print name: .....Kevin Hollingsworth......................................... Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
+ See chapter 19 for defined terms.
24/10/2005 Appendix 4C Page 5
Notes
1. The quarterly report provides a basis for informing the market how the entity’s
activities have been financed for the past quarter and the effect on its cash position.
An entity wanting to disclose additional information is encouraged to do so, in a note
or notes attached to this report.
2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this
report except for the paragraphs of the Standard set out below.
• 6.2 - reconciliation of cash flows arising from operating activities to
operating profit or loss
• 9.2 - itemised disclosure relating to acquisitions
• 9.4 - itemised disclosure relating to disposals
• 12.1(a) - policy for classification of cash items
• 12.3 - disclosure of restrictions on use of cash
• 13.1 - comparative information
3. Accounting Standards. ASX will accept, for example, the use of International
Accounting Standards for foreign entities. If the standards used do not address a topic,
the Australian standard on that topic (if any) must be complied with.
This should be a real barn burner for the long-term. My short term concern would be if insiders start selling like they did last time it was in this price range.
What would be wrong with focusing on the Florida JV using the JV funds to get the 45 sites up and running asap? It has all the same issues as building the company P2O machines (like permits) but it does not require dilution at this level as I am quite sure that after the 45 P2O machines are running and URS confirming plus up-listing and wide media coverage the price of JBII would be much higher. Would this be in shareholders best interest?
Agreed - Good place to start/add/avg-down IMHO
Yes $3.37 - looks like it's time to get back into CELH and maybe hold it long-term as I don't see it loosing any ground in the marketplace. I do wish they would change to using stevia for the sweetener and then I might be buying the product for myself.
"Survivor Itronics" sounds like a TV show. Doc Whitney has the immunity idle (spelled wrong on purpose) and his team is starting to win the challenges. Could this be the turning point for our green hero? Stay tuned. Same bat stock symbol but the bat channel is 10x larger and growing. LOL
Ok let's talk about what you did respond to. Generally anything new is very slow to be adopted in the medical profession if the same "basic" results can be obtained with the current methods. You could argue that the LTC results are superior and I would not disagree but I still think that getting the financial decision makers in the medical community to "see" the benefit is not going to be very fast or easy.
Will the bean counters at hospitals be willing to buy "new" (as in additional) equipment and then spend for the training?
Where LTC shines is in the places where it can do procedures not easy or even safely possible with the current methods (like lungs) but unfortunately LTC is not FDA yet approved for these procedures.
As I said before, I hope I am wrong and I hope CTGI makes everyone money.
In all honesty, I do want to see the LTC tech succeed but I do not know how you can be so confident with so many major unknowns...
1) what happened to the 25 million shares that were issued? Will there be more surprise share issues?
2) what percentage of LTC does CTGI own now and will they give up more before LTC starts generating income?
3) what is the new managements compensation and burn rate.
4) what makes you think that LTC can break into the duct and vessel market and be price competitive?
5) what if the whole market goes down again will CTGI follow like last time (was not that the major excuse for drop from over $2 to under $.10)?
6) what happens when the restrictions come off on the lawsuit shares (next month)?
I know they also have the carbon capture tech and I admit that I know very little about it but there seems to be a lot of competition in that field and even the company has stated that they are focused on LTC first.
You can ignore me but these are real and honest questions that keep me from re-entering CTGI at this time.
It has to be a scam right? JB not taking someones money? Where is the SEC when you need them?
Another company with super secret processes?
Thanks for your great picks TurtleBK. I also appreciate the picks that are real businesses that are undiscovered or in turnaround for long term gains as I try to avoid the day trader/momo players. I am happy with the two picks I have and expect much more out of both of them over time.
Take a look at ITRO and let me know what you think. It looks to me like it is in turnaround mode but they do have a convertible note that is haunting them. With their expansion plans (10x in progress to be followed by another 10x for a total of 100x production over current) I think they will break free and soar this year. I like that they are in fertilizers and silver with new prospects for environmentally friendly mining.
Nice PPS response to the news. We will see if it holds after the mo-mo is spent.
Earth Day - How about some pictures or video of streams polluted by photo chemicals and then a plug for ITRO to save the day? Sierra Club we need your help to get the word out. Be sure to zoom in on the dead fish and bears eating the toxic fish. Show Dr. Whitney the movie "wag the dog" and help him see how important perception is.
$holdier Hard - Thanks for all you do as mod here. Tough to put up with all the negative posts.
I tried to explain it to the board here but I guess they all put me on ignore?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47715664
A lot can happen in two months. If in the next two months P2O can garner a much wider exposure and if JBII can get an uplisting to AMEX or NASDAQ, THEN volume should not be an issue as there would be larger investors looking to pick up big blocks if someone wanted out in a big way. It all depends on if JB can convince the market that he has a real and solid plan that will work. If JB fails to convince the market or fails to get wider exposure then the stock will fall until revenues validate his claims (even if all his claims on P2O are true).
First, I would like to apologize on behalf of those of us who are long JBII stock and yet are unable to hold reasonable pro/con dialog. Some have "battle fatigue" from answering the same questions day after day, over and over for many months. Please understand that this is also a problem for those who do not believe the claims made in JBII filings in that they too can be very unreasonable. Egos have left little room for the middle ground.
I want to thank you for your observations and for taking time to put them in writing and expressing your reasoning in a very nonthreatening fashion.
You make some very good points about the JBII stock getting to the next level. I also have some of these concerns and agree that the posts here promoting JBII often seem confrontational and would not be impressive to savvy, higher wealth investors. However, JohnB appears to have put himself into a position that would only payoff for him personally if the P2O process works in a highly efficient method with long-term growth. I like to follow Scandle34 and E_P posts as they appear reasonable to me and I just skim most of the others. I wish the BB-OTC "DD" tactics would move on and change to the "Big Board" tactics for discussion (with egos and attitudes in check) but I have no control over that and it does not change the reality of the situation. It comforts me to know that JohnB had a couple of hundred investors in the original business before the R/M into 310. Do you know a couple of hundred people who would trust you and invest in your private business?
Now, I do think that mistakes have been made and to pretend that every decision has been the right decision at the right time is not credible. Fortunately many good decisions have been made but so far it appears to me that the Javaco purchase was a mistake. It was way too soon to be looking at third world partners and any dealing with Kidd will have a negative appearance no matter what. It may turn out "OK" in the long run but "at best" I see it as an unnecessary distraction for this point in time. Fortunately, JohnB seems smart enough to learn from his mistakes and I don't see Javaco as a real hindrance to the growth of the P2O business (which is why we are all here). I do think that if they learned from the last PR blitz and can get some "good" media coverage, then the next lever of "awareness" could come quite rapidly and if the P2O machines that they already have built start generating the cash flow that has been projected, then they might be able to expand with the JV's and loans and not have to rely as much on using the stock as financing while maintaining respectable growth.
Be sure to vote your shares. JohnB says he is not voting his majority shares so your vote does count. I will not be able to attend but I already voted.
;) - Also, a prescription might be required for those who bought under $.50 (LOL) ...
http://www.theonion.com/video/fda-approves-depressant-drug-for-the-annoyingly-ch,14310/
Lotus Pharmaceuticals' Innovative Drug to Receive SFDA Fast Track Approval
Date : 04/20/2010 @ 1:22PM
Source : PR Newswire
Stock : Lotus Pharmaceuticals (BB) (LTUS)
Quote : 1.13 0.11 (10.78%) @ 5:51PM
Lotus Pharmaceuticals' Innovative Drug to Receive SFDA Fast Track Approval
PR Newswire
BEIJING, April 20 /PRNewswire-Asia-FirstCall/ --
Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing
developer, manufacturer and seller of medicine and drugs in the People's
Republic of China (the "PRC") reported that its asthma drug Laevo-Bambutero
will receive the China's State Food & Drug Administration's (SFDA) Fast Track
Approval to enter clinical trials. The SFDA's Drug Review and Evaluation
Center told the Company during recent consultations at the end of the
Company's IND (Investigative New Drug Application) that formal approval would
be granted by the Beijing office of the SFDA.
Laevo-Bambutero has completed the SFDA special review process under
Category Two of the four categories of drugs that can receive speedier
approval for IND, clinical trials and new drug production. SFDA issues special
review and fast-track approval procedures for new drugs in 2009, under the
following four categories of drugs:
1) New active pharmaceutical ingredients (APIs) extracted from plants,
animals or minerals, and newly discovered traditional Chinese medicines
(TCM), along with their preparations, and products that are not sold in
the domestic market;
2) Drugs, and their APIs, preparations, and biological products, have not
been approved in the domestic and overseas market;
3) New drugs with superior efficacy for AIDS, malignant tumors and other
rare diseases; and
4) New drugs for diseases for which there is no existing effective
treatment.
CEO, Dr. Zhongyi Liu, commented, "Millions of people are suffering from
asthma worldwide, and 30-40 millions of asthma patients are estimated in China.
It took ten years to develop Laevo-Bambutero, and we own its patent rights
until 2022. We believe it is highly effective and has few side effects. We
hope to accelerate the new tablet introduction to market and
commercialization."
China's pharmaceutical industry has undergone the transformation from a
generic-dominated model to the one that promotes drug innovation. The SFDA's
Amended Measures effective in October of 2007 are intended to increase drug
safety, tighten appraisal and approval processes while encouraging innovation.
Given the SFDA's strict implementation of the Amended Measures, the Company
believes that product pipeline pending SFDA approval status should only
include Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular
disease, Gliclazide-Controlled Release Tablets for Type 2 diabetes and
Laevo-Bambutero for asthma.
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs
and a licensed national seller of pharmaceutical items in the PRC. Lotus
operates its business through its two controlled entities: Liang Fang
Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current
drug development is focused on the treatment of cerebro-cardiovascular disease,
asthma, and diabetes. Liang Fang sells drugs directly and indirectly through
its national sales channels to hospitals, clinics and drugs stores in 30
provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may," or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
could cause the actual results of the Company to differ materially from the
results expressed or implied by such statements, including, but not limited to,
changes from anticipated levels of sales, future national or regional economic
and competitive and regulatory conditions, changes in relationships with
customers, access to capital, increased costs, difficulties in developing and
marketing new products, marketing existing products, customer acceptance of
existing and new products, the time to get new drugs approved by the State
Food and Drug Administration and other factors. Additional information
regarding risks can be found in the Company's Annual Report on Form 10K and
its other filings with the SEC. Accordingly, although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, there can be no assurance that such expectations will prove to be
correct. The Company has no obligation to update the forward-looking
information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.com
SOURCE Lotus Pharmaceuticals, Inc.
Acro, Inc. Introduces Explosives Detection Products at the Counter Terror Expo 2010 in London
Date : 04/20/2010 @ 5:54PM
Source : MarketWire
Stock : Acro, Inc. (ACRI)
Quote : 0.041 0.001 (2.50%) @ 4:00PM
Acro, Inc. Introduces Explosives Detection Products at the Counter Terror Expo 2010 in London
CAESAREA, ISRAEL -- (Marketwire)
04/20/10
Acro, Inc. (OTCBB: ACRI), a leading manufacturer of explosive detection solutions for the homeland security market and related sectors, today announced that it unveiled its all-new ACRO-Mini-ETK and ACRO- CH.E.T. products at the Counter Terror Expo 2010 in London.
"We had a very successful showing of our newest products at the Counter Terror Expo last week," said Gadi Aner, President and Chief Executive Officer of Acro, Inc. "Our UK representatives reported that traffic to our exhibition booth was non-stop and received a lot of interest in our products from potential customers in the UK."
The ACRO-Mini-ETK contains four crushable ampoules protected by plastic mini tubes, filled with liquid reagents for the detection of explosives. Each kit contains sampling paper, a quick reference table and instructions. This compact kit distinguishes between explosive and non-explosive materials. Furthermore, the kit is capable of identifying four classes comprising the majority of explosives currently in use and revealing their traces on the body and various items such as clothes, suitcases, door handles and car surfaces and has been successfully used by Israeli police and security forces of other countries around the world. The ACRO-CH.E.T. (Chlorates Explosives Tester) is a light, easy-to-use, disposable, pocket-sized device that immediately and accurately identifies chlorate based explosives and can be used independently or as part of a total systems solution. The ACRO-CH.E.T. has low false positive and negative alarm rates, is very sensitive and can detect 10 micrograms of chlorate based explosives traces.
The Counter Terror Expo offers a secure exhibition showcasing the latest solutions dedicated to the counter terrorism and specialist security arena. The products and technologies shown in the exhibition form a crucial part of counter terror capabilities. The exhibition features over 300 international leading vendors.
About Acro:
Acro, Inc. develops explosives detection technologies and manufactures relevant products. In addition to the explosives detectors that are currently marketed by Acro, the company continues to develop proprietary technologies for the HLS market. Acro's Advisory Board includes Nobel Prize laureate Prof. K. Barry Sharpless, and Prof. Richard A. Lerner, President and CEO of The Scripps Research Institute, one of the most influential scientific institutes worldwide. For more information about Acro, visit www.AcroSec.com.
Forward-Looking Statement
This press release
contains forward-looking statements concerning our marketing and operations plans. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. All forward-looking statements in this press release are made based on management's current expectations and estimates, which involve risks, uncertainties and other factors that could cause results to differ materially from those expressed in forward-looking statements. These statements involve a number of risks and uncertainties including, but not limited to, risks related to the evolving homeland security market, general economic conditions and other risk factors. Acro does not undertake any obligation to update forward-looking statements made herein.
For more information please contact:
Acro, Inc.
info@AcroSec.com
Angioblast (of which Mesoblast owns a nice %) is mentioned in these clinical trials ...
http://www.clinicalconnection.com/exp/ExpandedPatientViewStudy176255.aspx
http://www.clinicalconnection.com/exp/ExpandedPatientViewStudy233089.aspx
http://www.clinicalconnection.com/exp/ExpandedPatientViewStudy190182.aspx
http://www.clinicalconnection.com/exp/ExpandedPatientViewStudy527538.aspx
The Stevia market is on the verge of an explosion.
The CEO voluntarily returned 30 million of his personally owned shares to the company treasury for asset purchases (over $100 million dollars worth). In exchange, he received "non-tradable super voting" shares (to remain in control of his company which he was already the majority shareholder) and now you want to make a big stink over 12,000 shares???
Inconceivable. Anyone who has been following this company laughs as such reasoning.
BIOLASE Awarded New Laser Diode Patent
Date : 04/14/2010 @ 6:00AM
Source : MarketWire
Stock : BIOLASE Technology, Inc. (BLTI)
Quote : 1.95 0.0 (0.00%) @ 7:22AM
BIOLASE Awarded New Laser Diode Patent
IRVINE, CA -- (Marketwire)
04/14/10
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced that it was awarded a new patent (U.S. Patent number 7,695,469 B2), based on a patent application that was filed in 2007, for technology that is utilized in the groundbreaking ezlase? and iLase? diode lasers.
The patent, granted yesterday, contains 20 separate claims. The patent describes some of the technology found in the ezlase and also contains drawings of two additional battery-powered, stand-alone lasers that were under development at the time of filing. One of those lasers is completely wireless, and shows an earlier concept of what became the iLase. It illustrates the display, controls, laser and batteries, all included as part of a single cylindrical handpiece. The iLase of today incorporates the latest laser technologies and a unique patent-pending 360 degree control switch right on the handpiece, eliminating the need for a footswitch.
David M. Mulder, Chief Executive Officer of BIOLASE, stated, "We are very pleased to now have an issued patent covering some of the key technologies that were the conception of and resulted in the launch of iLase this year. This issued patent is illustrative of our robust intellectual property portfolio and our leadership position in lasers. We look forward to bringing forward more of those innovations to further enhance the world of dental and medical care."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact: Jill Bertotti (investor) and Len Hall (media), of Allen & Caron, +1-949-474-4300.
Kinda like this site did to SI?
How is "ethanol is a god example" ? Please explain
phoprox - you know this is a REAL company with great technology and very limited resources. Mistakes have been made - granted no argument there. However, the current Forbes article appears to be referencing events of several years ago which is sloppy journalism and misleading because no time frame was referenced.